Scots-Knight Denise's Form 4 filing
Mereo BioPharma Group plc (MREO) · filed Sep 16, 2024
- Accession no.
- 0000950170-24-106976
- Filed
- Sep 16, 2024
- Trade date
- Sep 12-13, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $381.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scots-Knight DeniseCIK 0001297000 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2024 | American Depositary Shares representing Ordinary Shares | SSaleDisposed | −28,611 | $4.47 | −$127,891.17 | 868,967 | Direct | |
| Sep 13, 2024 | American Depositary Shares representing Ordinary Shares | SSaleDisposed | −60,046 | $4.22 | −$253,394.12 | 808,921 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.